成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. Immunology/Inflammation NF-κB Metabolic Enzyme/Protease Apoptosis
  3. COX Reactive Oxygen Species Apoptosis Ferroptosis Endogenous Metabolite
  4. Gallic acid

Gallic acid  (Synonyms: 沒食子酸; 3,4,5-Trihydroxybenzoic acid)

目錄號: HY-N0523 純度: 99.99%
COA 產(chǎn)品使用指南 技術(shù)支持

Gallic acid (3,4,5-Trihydroxybenzoic acid) 是一種天然多羥基酚類化合物，具有抑制環(huán)氧合酶-2 (COX-2) 的自由基清除作用。Gallic acid 具有多種活性，如抗菌、抗氧化、抗菌、抗炎和抗腫瘤活性。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務(wù)

Gallic acid Chemical Structure

Gallic acid Chemical Structure

CAS No. : 149-91-7

1.  客戶無需承擔(dān)相應(yīng)的運輸費用。

2.  同一機構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機構(gòu)（單位）一年內(nèi)

     可免費申領(lǐng)三個不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ￥550
In-stock
50 mg ￥263
In-stock
100 mg ￥500
In-stock
500 mg ￥700
In-stock
1 g   詢價  
5 g   詢價  

* Please select Quantity before adding items.

Customer Review

Other Forms of Gallic acid:

查看 COX 亞型特異性產(chǎn)品:

  • 生物活性

  • 實驗參考方法

  • 純度 & 產(chǎn)品資料

  • 參考文獻

生物活性

Gallic acid (3,4,5-Trihydroxybenzoic acid) is a natural polyhydroxyphenolic compound and an free radical scavenger to inhibit cyclooxygenase-2 (COX-2)[1]. Gallic acid has various activities, such as antimicrobial, antioxidant, antimicrobial, anti-inflammatory, and anticance activities[2].

IC50 & Target[1]

COX-2

 

Microbial Metabolite

 

Human Endogenous Metabolite

 

細胞效力
(Cellular Effect)
Cell Line Type Value Description References
A549 IC50
0.4 mM
Compound: Gallic acid
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
[PMID: 27162124]
A549 IC50
0.4 mM
Compound: Gallic acid
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by FMCA assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by FMCA assay
[PMID: 27162124]
A549 IC50
0.4 mM
Compound: Gallic acid
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by luminescence-based ATP assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by luminescence-based ATP assay
[PMID: 27162124]
CCRF-CEM IC50
> 200 μM
Compound: GA
Cytotoxicity against human CCRF-CEM cells after 48 hrs by neutral red assay
Cytotoxicity against human CCRF-CEM cells after 48 hrs by neutral red assay
[PMID: 24568614]
CCRF-CEM IC50
> 50 μM
Compound: 0, Gallic acid
Cytotoxicity against human CEM cells after 24 hrs by MTT assay
Cytotoxicity against human CEM cells after 24 hrs by MTT assay
[PMID: 18295493]
CCRF-CEM IC50
> 50 μM
Compound: 0, Gallic acid
Cytotoxicity against human CEM cells after 72 hrs by MTT assay
Cytotoxicity against human CEM cells after 72 hrs by MTT assay
[PMID: 18295493]
CCRF-CEM EC50
> 50 μM
Compound: 1
Antiviral activity against HIV1 3B infected in human CEM cells assessed as reduction in virus-induced cytopathicity after 4 to 5 days by microscopy based syncytium cell formation assay
Antiviral activity against HIV1 3B infected in human CEM cells assessed as reduction in virus-induced cytopathicity after 4 to 5 days by microscopy based syncytium cell formation assay
[PMID: 25617695]
CCRF-CEM EC50
> 50 μM
Compound: 1
Antiviral activity against HIV2 ROD infected in human CEM cells assessed as reduction in virus-induced cytopathicity after 4 to 5 days by microscopy based syncytium cell formation assay
Antiviral activity against HIV2 ROD infected in human CEM cells assessed as reduction in virus-induced cytopathicity after 4 to 5 days by microscopy based syncytium cell formation assay
[PMID: 25617695]
Erythrocyte IC50
0.59 mM
Compound: 18
Anticomplement activity in sheep erythrocytes assessed as concentration required for 50% hemolytic inhibition by classic pathway pretreated for 10 mins with guinea pig serum followed by erythrocyte addition measured after 30 mins by spectrophotometeric me
Anticomplement activity in sheep erythrocytes assessed as concentration required for 50% hemolytic inhibition by classic pathway pretreated for 10 mins with guinea pig serum followed by erythrocyte addition measured after 30 mins by spectrophotometeric me
[PMID: 29631958]
Erythrocyte IC50
0.74 mM
Compound: 18
Anticomplement activity in rabbit erythrocytes assessed as concentration required for 50% hemolytic inhibition by alternative pathway pretreated for 10 mins with normal human serum followed by erythrocyte addition measured after 30 mins by spectrophotomet
Anticomplement activity in rabbit erythrocytes assessed as concentration required for 50% hemolytic inhibition by alternative pathway pretreated for 10 mins with normal human serum followed by erythrocyte addition measured after 30 mins by spectrophotomet
[PMID: 29631958]
HCT-116 IC50
41.8 μg/mL
Compound: Gallic acid
Anticancer activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
Anticancer activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
[PMID: 32731188]
HeLa IC50
26.3 μg/mL
Compound: Gallic acid
Anticancer activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
Anticancer activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
[PMID: 32731188]
HUVEC IC50
> 294 μM
Compound: 8
Cytotoxicity against HUVEC cells assessed as inhibition of cell growth incubated for 48 hrs by fluorescence based assay
Cytotoxicity against HUVEC cells assessed as inhibition of cell growth incubated for 48 hrs by fluorescence based assay
[PMID: 37122550]
L1210 IC50
> 50 μM
Compound: 0, Gallic acid
Cytotoxicity against mouse L1210 cells after 48 hrs by MTT assay
Cytotoxicity against mouse L1210 cells after 48 hrs by MTT assay
[PMID: 18295493]
L1210 IC50
50 μM
Compound: 0, Gallic acid
Cytotoxicity against mouse L1210 cells after 72 hrs by MTT assay
Cytotoxicity against mouse L1210 cells after 72 hrs by MTT assay
[PMID: 18295493]
MCF7 IC50
17.4 μM
Compound: Gallic acid
Cytotoxicity against human ER-positive MCF7 cells assessed as decrease in cell proliferation at 12.5 to 100 uM incubated for 24 hrs
Cytotoxicity against human ER-positive MCF7 cells assessed as decrease in cell proliferation at 12.5 to 100 uM incubated for 24 hrs
[PMID: 33711444]
RAW264.7 IC50
> 50 μM
Compound: 13
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 2 hrs followed by LPS stimulation and measured after 24 hrs by by Griess assay
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 2 hrs followed by LPS stimulation and measured after 24 hrs by by Griess assay
[PMID: 31419126]
RAW264.7 IC50
631.6 μM
Compound: gallic acid
Inhibition of LPS-induced NO production in mouse RAW264.7 cells assessed as reduction in nitrite level within 24 hrs by Griess reagent method
Inhibition of LPS-induced NO production in mouse RAW264.7 cells assessed as reduction in nitrite level within 24 hrs by Griess reagent method
[PMID: 22560043]
RAW264.7 IC50
69.25 μM
Compound: 3a
Antagonist activity at TLR2 in mouse RAW264.7 cells assessed as PAM3CSK4-induced NO production measured after 24 hrs by Griess assay
Antagonist activity at TLR2 in mouse RAW264.7 cells assessed as PAM3CSK4-induced NO production measured after 24 hrs by Griess assay
[PMID: 31255924]
體外研究
(In Vitro)

Gallic acid 是一種抗氧化劑，可抑制 COX-2[1]。用 Gallic acid 處理 18 小時后，活中性粒細胞的數(shù)量從 40.3% 急劇下降到 27.7%，與未經(jīng)處理的中性粒細胞的 26.4% 相當(dāng)。Gallic acid 不能減弱異丙腎上腺素誘導(dǎo)的肌細胞溶解[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
體內(nèi)研究
(In Vivo)

Gallic acid 組的食物攝入量 (2.6±0.08 g/天，p=0.69) 和體重 (2.5±0.69 g，p=0.76) 與對照組 (食物攝入量；2.41± 0.14 克/天和體重；2.83±0.84 克/天)。Gallic acid 組的血糖耐量在處理2周后明顯改善。Gallic acid 組在處理 2 周后的血糖耐量在 90 分鐘和 120 分鐘時也明顯優(yōu)于對照組 (p<0.05)。Gallic acid 組的血清甘油三酯濃度 (0.67±0.03 mM，p<0.05) 相對于對照組 (1.08±0.20 mM) 顯著降低。對照組 (3.19±0.27 mM) 和 Gallic acid (3.01±0.18 mM) 組的總膽固醇濃度相似[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

170.12

Formula

C7H6O5
CAS 號
性狀

固體

顏色

White to off-white

中文名稱

沒食子酸
結(jié)構(gòu)分類
初始來源
運輸條件

Room temperature in continental US; may vary elsewhere.
儲存方式

Store at room temperature 3 years

In solvent -80°C 2 years
-20°C 1 year
溶解性數(shù)據(jù)
細胞實驗： 

DMSO 中的溶解度 : ≥ 100 mg/mL (587.82 mM; 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響，請使用新開封的 DMSO)

H2O 中的溶解度 : 8.33 mg/mL (48.97 mM; 超聲助溶 (<60°C))

* "≥" means soluble, but saturation unknown.

配制儲備液
濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
1 mM 5.8782 mL 29.3910 mL 58.7820 mL
5 mM 1.1756 mL 5.8782 mL 11.7564 mL
查看完整儲備液配制表

* 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲備液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C儲存時，請在2年內(nèi)使用，-20°C儲存時，請在1年內(nèi)使用。

* 備注：如您選擇水作為儲備液，請稀釋至工作液后，再用 0.22 μm 的濾膜過濾除菌后使用。

  • 摩爾計算器

  • 稀釋計算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質(zhì)量
=
濃度
×
體積
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

濃度 (start)

C1

×
體積 (start)

V1

=
濃度 (final)

C2

×
體積 (final)

V2

動物實驗：

請根據(jù)您的 實驗動物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：
——為保證實驗結(jié)果的可靠性，澄清的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實驗的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

  • 方案 一

    請依序添加每種溶劑： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (14.70 mM); 澄清溶液

    此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。

    以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

    生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
  • 方案 二

    請依序添加每種溶劑： 10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (14.70 mM); 澄清溶液

    此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。

    以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中，混合均勻。

    2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。

以下溶解方案，請直接配制工作液。建議現(xiàn)用現(xiàn)配，在短期內(nèi)盡快用完。 以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比； 如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶。

  • 方案 一

    請依序添加每種溶劑： Corn Oil

    Solubility: 20 mg/mL (117.56 mM); 懸濁液; 超聲助溶

動物溶解方案計算器
請輸入動物實驗的基本信息：

給藥劑量

mg/kg

動物的平均體重

g

每只動物的給藥體積

μL

動物數(shù)量

只
由于實驗過程有損耗，建議您多配一只動物的量
請輸入您的動物體內(nèi)配方組成：
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
如果您的動物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。
方案所需 助溶劑 包括：DMSO， ，均可在 MCE 網(wǎng)站選購。 ，Tween 80，均可在 MCE 網(wǎng)站選購。
計算結(jié)果
工作液所需濃度 : mg/mL
儲備液配制方法 : mg 藥物溶于 μL  DMSO（母液濃度為 mg/mL）。
您所需的儲備液濃度超過該產(chǎn)品的實測溶解度，以下方案僅供參考，如有需要，請與 MCE 中國技術(shù)支持聯(lián)系。
動物實驗體內(nèi)工作液的配制方法 : 取 μL DMSO 儲備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。
連續(xù)給藥周期超過半月以上，請謹慎選擇該方案。
請確保第一步儲備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱 （超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。
純度 & 產(chǎn)品資料

純度: 99.99%

參考文獻
Cell Assay
[3]

Neutrophils are treated with 8?μg/mL Gallic acid in RPMI1640/10% FBS for 3, 6, 9, and 18?h. At the end of Gallic acid treatment, the cells are stained with Annexin V-FITC and PI according to manufacturer's instructions. Briefly, the cells are washed twice with ice-cold PBS and resuspended in 1× Binding Buffer at a concentration of 1×106 cells/mL. Cell suspensions (1×105 cells in 100?μL) are incubated with 5?μL of Annexin V-FITC and 10?μL PI in a 5?mL culture tube at room temperature for 20?min. The stained cells are immediately analyzed on flow cytometry system[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration
[2]

Five-week-old male C57BL/6 mice are used in this study. The animals are maintained in a temperature-controlled room at 22° C on a 12 h light-dark photocycle. The mice are divided into the control vehicle group and the Gallic acid group. For 2 weeks, the mice are administered intraperitoneal treatment on a daily basis with vehicle (10% alcohol, 10% tween 80, and 80% saline) alone or with 10 mg/kg Gallic acid. After this treatment, GTTs are again conducted, and the blood samples are taken for subsequent biochemical analysis. Over the experimental period, food intake and body weight are measured on a daily basis[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
參考文獻

完整儲備液配制表

* 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲備液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C儲存時，請在2年內(nèi)使用，-20°C儲存時，請在1年內(nèi)使用。

可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
H2O / DMSO 1 mM 5.8782 mL 29.3910 mL 58.7820 mL 146.9551 mL
5 mM 1.1756 mL 5.8782 mL 11.7564 mL 29.3910 mL
10 mM 0.5878 mL 2.9391 mL 5.8782 mL 14.6955 mL
15 mM 0.3919 mL 1.9594 mL 3.9188 mL 9.7970 mL
20 mM 0.2939 mL 1.4696 mL 2.9391 mL 7.3478 mL
25 mM 0.2351 mL 1.1756 mL 2.3513 mL 5.8782 mL
30 mM 0.1959 mL 0.9797 mL 1.9594 mL 4.8985 mL
40 mM 0.1470 mL 0.7348 mL 1.4696 mL 3.6739 mL
DMSO 50 mM 0.1176 mL 0.5878 mL 1.1756 mL 2.9391 mL
60 mM 0.0980 mL 0.4899 mL 0.9797 mL 2.4493 mL
80 mM 0.0735 mL 0.3674 mL 0.7348 mL 1.8369 mL
100 mM 0.0588 mL 0.2939 mL 0.5878 mL 1.4696 mL

* 備注：如您選擇水作為儲備液，請稀釋至工作液后，再用 0.22 μm 的濾膜過濾除菌后使用。

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的產(chǎn)品:

Your information is safe with us. * Required Fields.

   產(chǎn)品名稱：

  

* 需求量：

* 客戶姓名：

 

* Email：

* 電話：

 

* 公司或機構(gòu)名稱：

   留言給我們：

Bulk Inquiry

Inquiry Information

產(chǎn)品名稱：
Gallic acid
目錄號：
HY-N0523
需求量：